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This study investigated the relationship of children’s autism symptoms with their toxic metal body burden and red blood cell
(RBC) glutathione levels. In children ages 3–8 years, the severity of autism was assessed using four tools: ADOS, PDD-BI,
ATEC, and SAS. Toxic metal body burden was assessed by measuring urinary excretion of toxic metals, both before and after
oral dimercaptosuccinic acid (DMSA). Multiple positive correlations were found between the severity of autism and the urinary
excretion of toxic metals. Variations in the severity of autism measurements could be explained, in part, by regression analyses of
urinary excretion of toxic metals before and after DMSA and the level of RBC glutathione (adjusted R2 of 0.22–0.45, P<. 005 in
all cases). This study demonstrates a signiﬁcant positive association between the severity of autism and the relative body burden of
toxic metals.
Copyright © 2009 J. B. Adams et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Background
Autism is a severe developmental disorder which involves
social withdrawal, communication deﬁcits, and stereo-
typic/repetitive behaviour. The pathophysiological etiologies
which precipitate autism symptoms remain elusive and con-
troversial in many cases, but both genetic and environmental
factors (and their interactions) have been implicated. One
environmental factor that has received signiﬁcant attention
is the body burden of mercury, lead, and other toxic metals
[1–5].
Bernardetal.[1]discussedthemanysimilaritiesbetween
thesymptomsofchildrenwithautismandchildrenpoisoned
by mercury. An epidemiology study by Windham et al. [2]
found that the amount of airborne pollutants, and especially
mercury, correlated with an increased risk for autism. A
study by DeSoto and Hitlan [3] found that blood levels
of mercury did signiﬁcantly correlate with the diagnosis
of autism. A small study by Adams et al. [4] found that
children with autism had a 2-time higher level of mercury in
their baby teeth than typical children. A study by Bradstreet
et al. [5] investigated the body burden of toxic metals by
giving dimercaptosuccinic acid (DMSA), an oral chelation
medication approved by the FDA for treating infantile lead
poisoning.Theyfoundthatthechildrenwithautismexcreted
3.1 times as much mercury into their urine (which is where
DMSA is excreted), P<. 0002, but lead and cadmium
levels were not signiﬁcantly diﬀerent. Overall there is some
evidence to suggest that mercury and possibly other toxic
metals are related to the etiology of autism.
This study investigates the possible relationship of the
severity of autism to the relative body burden of toxic
metals. The severity of autism was assessed using four tools,
a professional evaluation based on the Autism Diagnostic
ObservationSchedule[6], and parental evaluations based on
the Pervasive Developmental Disorders Behaviour Inventory2 Journal of Toxicology
(PDD-BI) [7], the Autism Treatment Evaluation Checklist
(ATEC) [8], and the Severity of Autism Scale (SAS). The
individual burden of toxic metals was assessed based on
urinary excretion, both before and after taking oral dimer-
captosuccinic acid (DMSA). DMSA is a licensed medication
for treating lead poisoning and indicated in cases meeting
toxic criteria. DMSA is, however, widely used oﬀ-label
for other metal exposures, for example, mercury. It acts
by forming sulfhydryl linkages to divalent metal cations,
forming a chelated metal complex which is then excreted in
the urine [9]. Urine measurements before and after taking
DMSAprovideanindicationofbothongoingenvironmental
exposures (before DMSA provocation) and the accumulated
or relative body burden (postprovocation with DMSA). Red
blood cell (RBC) glutathione was measured because it is
one of the body’s primary means for excretion of toxic
metals.
This paper investigates the possible relationship of the
severity of autism to the body burden of toxic metals and
RBC glutathione levels. This paper is part of a larger study
which investigates the safety and eﬃcacy of DMSA therapy,
including both the biological consequences [10] and the
DMSA associated behavioural eﬀects [11]. The larger study
involves a 3-day round of DMSA, to screen for admission
into a 3-month DMSA treatment study; only children with
high levels of urinary toxic metals were admitted into the
long-term 3-month treatment study.
2. Methods
The methodology is discussed in detail in the companion
paper [10]. Brieﬂy, this study was conducted with the ap
proval of the Human Subjects Institutional Review Board of
SouthwestCollegeofNaturopathicMedicine.Allparentsand
(where possible) children signed informed consent/assent
forms. The study participants were recruited in Arizona,
with the help of the Autism Society of America—Greater
PhoenixChapterandtheArizonaDivisionofDevelopmental
Disabilities.
The entry criteria were the following.
(1) Children with autism spectrum disorder, diagnosed
by a psychiatrist, psychologist, or developmental
pediatrician.
(2) Age 3–8 years.
(3) No mercury amalgam dental ﬁllings (due to a
concern of their interaction with DMSA).
(4) No previous use of DMSA or other prescription
chelators.
(5) No anemia or currently being treated for anemia due
to low iron.
(6) No known allergies to DMSA.
(7) No liver or kidney disease.
(8) Children are well hydrated (receiving adequate daily
intake of water).
Four metrics were employed to assess the severity of
autism: the PDD-BI, ATEC, SAS, and ADOS. Multiple
assessment instruments were selected because they each
provide insights into various aspects of autism. The ATEC
was completed approximately 2-3 weeks prior to taking the
DMSA, and the other three instruments were completed
approximately 2–4 weeks after the initial 3-day round
of DMSA, for children whose excretion of toxic metals
was deemed high enough to warrant continuation in the
long-term treatment study. The ATEC, PDD-BI, and SAS
were assessed by the participant’s parents, and the ADOS
evaluation was performed by a certiﬁed ADOS evaluator. It
should be noted that the ADOS was developed primarily for
diagnosing autism, whereas the other tools were developed
for assessing changes in autistic symptoms during treatment
studies.
DMSA was administered orally in 9 doses of 10mg/kg,
3 times daily, over 3 days. Urine was collected for approxi-
mately 8 hours prior to taking the DMSA, and for approxi-
mately 8 hours immediately after the 9th dose, in a process
similar to a previous retrospective study of relative body
burden of heavy metals [2]. RBC glutathione was measured
approximately 1-2 weeks prior to taking the DMSA. The
details of measuring the urinary metals and RBC glutathione
are given in [10].
The PDD-BI is composed of many subscales. One of
the subscales, the Semantic/Pragmatic Problems (SPPs), was
diﬃcult to interpret, since children with no spoken language
i n a p p r o p r i a t e l ys c o r e da sl e s ss e v e r e l ya ﬀected than those
with limited language. Therefore, we exclude the SPP sub-
scale in the Autism Composite score, resulting in a modiﬁed
Autism Composite score consisting of Sensory/Perceptual
Approach, Ritualisms/Resistance to Change, Social Prag-
matic Problems, Social Approach Behaviors, Phonological
and Semantic Pragmatic subscales. This modiﬁed Autism
Composite score was discussed with I. Cohen, the developer
ofthePDD-BI.Webelievethatthismodiﬁedsubscaleismore
usefulbecauseseveralchildreninitiallywithoutspeechbegan
talking after DMSA treatment in the study. The development
of speech led to a worsening of their score on the SPP,
because a nonverbal child is given a score of zero (indicating
no semantic/pragmatic problems, which is the same score
a typically developed child would receive) compared to a
child with limited speech but major semantic/pragmatic
problems who would receive a high score on the SPP.
Thus, we think the modiﬁed Autism subscale (without the
SPP) is more useful for children with very limited or no
language.
In order to assess global changes in autism severity, a new
metric was developed for this study. The Severity of Autism
Scale (SAS) is introduced for the ﬁrst time in this series of
papers. It is essentially a Clinical Global Impression scale
using a 0–10 severity scale, with the diﬀerence being that the
scale was made speciﬁc to autism by deﬁning the numeric
values (see below). The purpose of the tool is to provide a
simple, overall assessment of the severity of the symptoms
of autism. In this study we will analyze the correlation
of this scale with the other more established assessment
tools.Journal of Toxicology 3
Severity of Autism Scale:
0: normal,
1: slight symptoms of autism,
2–4, mild symptoms of autism,
5–7, moderate symptoms of autism,
8–10, severe symptoms of autism.
63 participants were assessed with the ATEC, and 49
participantswereassessedwiththePDD-BI,SAS,andADOS.
Fewer participants were assessed for the latter three tests
because some participants had low urinary excretion of
toxic metals and were not eligible to continue, and some
participants dropped out.
Table 1 lists the characteristics of the participants.
Table 2 lists their average urinary excretion of toxic
metals before and after taking DMSA.
2.1. Regression Analysis. Regression analysis was employed
to examine the relationship between the severity of autism
(assessed by the ATEC, PDD-BI, SAS, and ADOS) and the
urinary excretion of toxic metals, (both before and after
taking DMSA), and further with the initial glutathione
(in the red blood cells). For the selected dependent and
independent variables, stepwise linear regression analyses
were conducted: initially all independent variables were
included in the regression; then at each step, the variable
with the highest P-value was eliminated, and this process
was continued until the adjusted R2 value began declining.
Thus,thegoalwastodeterminethebestﬁttothesampledata
for the selected model, taking into account the correlation
among the independent variables. Since the data had several
missing values (due to missing lab or behavioural data),
the regression analyses were conducted in two slightly
diﬀerent ways which generally yielded very similar results:
(1) eliminate all participants with missing data for any of the
variables in the model at the beginning of the analysis, and
(2) eliminate participants on an as-needed basis (i.e., only
where there is missing data for any variable in the current
step in the analysis). Since these two methods yielded very
similar results, for brevity we only report the results for
method 1.
3. Results
3.1. Correlations of Severity Scales. Table 3 shows the correla-
tionsamongtheassessmentscales.Thereisahighcorrelation
between the ATEC and the PDD-BI (r = 0.87), and a good
correlation of the SAS with the ATEC (r = 0.70) and the
PDD-BI (r = 0.72). The correlation of the ADOS with the
other scales is somewhat lower (r = 0.60–0.67), probably
since the ADOS evaluation was done by a professional
evaluator, whereas the other assessments were done by the
same parent.
3.2. Correlation Analysis. Table 4 shows the results of a
simple correlation analysis of severity of autism versus toxic
metal levels. Correlations with a P-value of less than .05
Table 1: Characteristics of participants. The second number is the
standard deviation.
Total
Total participants 63
Male 57
Female 6
Age (years) 5.6 ± 1.6
Diagnosis 62 autism, 1 Asperger’s
ATEC (total) 62 ± 28
SAS 5.1 ± 2.2
ADOS (communication + social) 15.8 ± 6.5
PDD-BI (modiﬁed autism score) −54.3 ± 62
RBC glutathione (pre-DMSA) 501 ± 246 micromolar
Table 2: Urinary excretion of toxic metals in Phase 1, at baseline
and after 9th dose of DMSA, in mcg/g creatinine. Creatinine values
have units ofmg/dL. N = 63. The metals are listed in approximate
order of eﬀect of DMSA on excretion. Signiﬁcant results are
highlighted in bold font.
Element Baseline After 9th
dose
After 9th
dose versus
baseline
Pb 1.3 ±2.3 9.2 ±7.8 638%∗∗∗∗
Sn 2.3 ±3.4 9.7 ±24 314%∗∗
Bi 0.18 ±0.45 0.41 ±1.0 128%∗∗
U0 .015 ±.04 0.031 ±.1 111%
Hg 0.86 ±.92 0.97 ±0.88 13%
Tl 0.15 ±0.12 0.21 ±0.19 42%∗∗∗
Sb 0.10 ±0.10 0.14 ±0.20 42%∗
W0 .3 ±0.29 0.46 ±0.50 18%∗∗
Al 16 ±21 19 ±33 21%
Ni 6.7 ±5.1 7.6 ±4.3 12%
Cd 0.38 ±0.24 0.3 ±0.23 −14%
As 32 ±20 25 ±18 −19%∗∗
Creatinine 94 ±52 80 ±43 −15%∗∗
∗P<. 1, ∗∗P<. 05, ∗∗∗P<. 01, ∗∗∗∗P<. 001
Table 3: Correlation of autism severity scores.
ATEC total SAS ADOS (social +
communication)
PDD-BI (modiﬁed
autism score)
ATEC 1
SAS 0.70 1
ADOS 0.60 0.60 1
PDD-BI 0.87 0.72 0.67 1
are shown in bold. Baseline excretion of antimony (Sb) and
excretion of lead (Pb) after the 9th dose of DMSA are the
two most consistent factors, although other metals also have
P<. 05 for some of the severity scales. In all cases for P<. 05,
thecorrelationsarepositive,sothathighlevelsoftoxicmetals4 Journal of Toxicology
Table 4:Correlationanalysesofinitialautismseverityversusurinarymetalexcretionandinitialglutathione.Themetalexcretionismeasured
both at Baseline (before DMSA) and after the 9th dose of DMSA. The ﬁrst number in each cell is the correlation coeﬃcient (r) and the
second number is the P-value. Correlation coeﬃcients with P < .05 are in bold. The last 2 rows list the total number of positive and negative
correlation coeﬃcients, respectively.
ATEC total ADOS (social +
communication)
SAS PDD-BI (modiﬁed
autism score)
PbBase −0.00 (0.96) 0.11 (0.47) 0.50 (0.0002) 0.22 (0.12)
SnBase 0.16 (0.32) −0.11 (0.47) 0.12 (0.41) 0.09 (0.52)
TlBase 0.13 (0.32) 0.10 (0.49) 0.21 (0.15) 0.25 (0.077)
HgBase 0.13 (0.33) 0.05 (0.76) 0.15 (0.31) 0.18 (0.19)
SbBase 0.40 (0.002) 0.35 (0.02) 0.51 (0.0002) 0.42 (0.0023)
Wbase 0.16 (0.23) 0.07 (0.67) 0.26 (0.07) 0.17 (0.22)
AsBase 0.04 (0.74) −0.05 (0.73) 0.00 (0.98) 0.04 (0.76)
CdBase 0.00 (1.00) 0.11 (0.48) 0.03 (0.83) −0.10 (0.48)
AlBase −0.06 (0.65) −0.19 (0.20) −0.05 (0.73) 0.02 (0.87)
Pb9 0.27 (0.04) 0.34 (0.02) 0.36 (0.01) 0.42 (0.0027)
Sn9 −0.02 (0.88) 0.00 (0.98) 0.02 (0.87) −0.12 (0.42)
Tl9 0.26 (0.046) 0.11 (0.51) 0.27 (0.064) 0.24 (0.098)
Hg9 0.09 (0.52) 0.20 (0.18) −0.02 (0.91) 0.07 (0.59)
Sb9 0.03 (0.84) 0.20 (0.19) 0.38 (0.008) 0.26 (0.065)
W9 0.11 (0.42) 0.34 (0.02) −0.00 (0.99) 0.19 (0.18)
As9 0.19 (0.16) −0.24 (0.12) −0.24 (0.11) −0.04 (0.79)
Cd9 0.07 (0.58) 0.34 (0.024) 0.08 (0.57) 0.15 (0.29)
Al9 0.06 (0.65) 0.28 (0.059) 0.25 (0.089) 0.17 (0.24)
Glut1 0.25 (0.04) 0.34 (0.024) 0.25 (0.09) 0.26 (0.70)
Number of positive coeﬃcients 17 15 15 16
Number of negative coeﬃcients 2 4 4 3
correlate with higher severity of autism, as expected. Also,
the initial glutathione correlates positively with two of the
severity scales at P<. 05.
However, because we are analyzing many correlations, a
traditional P-value of <.05 is not a rigorous guide. Since we
are analyzing 76 possible correlations, random chance alone
would result in approximately 4 results at P<. 05. We found
13 instances of P<. 05 for toxic metals, and the probability
of that occurring randomly is 7 × 10
−5,s oi ti sv e r yl i k e l y
that most, but probably not all, of the correlations represent
actual relationships.
One way to deal with the problem of multiple correlation
analyses is the Bonferroni approach. Using this approach
involvesdividingthenominalP-valuebythenumberoftests,
so that for 95% conﬁdence one needs a P-value less than
.05/76, or P<. 0007. Using the Bonferroni approach, the
correlations between initial Severity of Autism Scale (SAS)
and baseline excretion of lead (Pb) and antimony (Sb) are
signiﬁcantlydiﬀerentfrom0atthe95%conﬁdencelevel,and
these are the only pairs that meet the Bonferroni criterion
for the 5% signiﬁcance threshold. Again, it should be noted
that this is a conservative approach, designed to ensure that
very few nonsigniﬁcant correlations are misrepresented as
signiﬁcant.
False discovery rate (FDR) is a less conservative method
for performing multiple hypothesis tests, based on con-
trolling the expected number of false positives among the
cases declared signiﬁcant. If we use FDR on the summary
severity scores, then in addition to the results obtained
from the Bonferroni analysis, the correlation between Initial
ATEC Total and baseline excretion of antimony (Sb), and
the correlations between Initial PDD-BI Autism Total and
baseline excretion of antimony (Sb) and 9th dose excretion
of lead (Pb) are signiﬁcantly diﬀerent from 0; we will term
these ﬁndings “marginally signiﬁcant.”
Next, consider the numbers of positive and negative
sample correlation coeﬃcients in the table. If there were no
statistically signiﬁcant correlations between autism severity
and biological measures then we would expect on average
about equal numbers of positive and negative sample
correlation coeﬃcients. For the summary severity measures,
we observed 63 positive sample correlation coeﬃcients (r’s)
and 13 negative r’s. This corresponds to a P-value of
3 × 10
−9 for the hypothesis that there is no correlation
between theseverity measuresandbiological measures.Thus
it is extremely likely that there is a high overall positive
correlation between the severity measures as a group and the
biological measures taken as a group.
Finally, the average of all of the 76 sample correlation
coeﬃcients is 0.14. If there were no statistically signiﬁcant
correlations between autism severity and the biological
measures, the average of 76 sample correlation coeﬃcientsJournal of Toxicology 5
Table 5: Regression analyses of initial autism severity versus urinary metal excretion and initial glutathione. In the regression equation, the
suﬃxes for the metals refer to the value at Baseline (B) and after the 9th (9) dose of DMSA in Phase 1.
Adjusted R2 P-value Equation Most signiﬁcant
variables
ATEC 0.22 .003 24.1–6.17HgB + 76.6SbB + 0.593Pb9 + 3.97Hg9 + 0.27As9 SbB∗∗,P b 9 ∗
SAS 0.36 .002 4.81 + 1.70PbB + 4.87TlB − 0.640HgB + 5.48SbB − 1.87CdB −
0.0237AlB − 0.114Pb9 − 3.14Tl9 + 6.07Sb9 PbB∗∗
ADOS (comm.
+s o c i a l )
0.45 .0003 13.19–4.29HgB + 24.1SbB − 3.67WB − 0.0673AlB + 2.75Hg9 +
6.60W9 − 0.0539As9 + 0.0054Glut
HgB∗∗,S b B ∗,
Hg9∗,W 9 ∗
PDD-BI
(modiﬁed
autism score)
0.25 .004 −131.8 + 70.4WB − 0.789Sn9 + 18.8Hg9 + 255Sb9 + 21.8W9 Sb9∗∗,W B ∗,S n 9 ∗
∗∗P<. 01, ∗P<. 05
Table 6: Regression analyses of initial ados subscales versus urinary metal excretion and initial glutathione. In the regression equation, the
suﬃxes for the metals refer to the value at Baseline (B) and after the 9th (9) dose of DMSA in Phase 1.
Adjusted R2 P-value Equation Most signiﬁcant
variables
ADOS-
Sociability
0.41 0.004
8.70 +1.20PbB + 0.217SnB + 12.7TlB − 1.64HgB − 10.2SbB −
2.61CdB − 0.631AlB − 0.186Pb9 − 7.13Tl9 + 6.27Sb9 +6.15W9
+3.62Cd9
W9∗∗∗,A l B ∗∗,
TlB∗,H g B ∗,P b 9 ∗,
Tl9∗
ADOS-
Commun.
0.37 0.0003 2.39–2.57HgB + 23.1SbB + 2.32Hg9 + .0048Glut HgB∗∗,H g 9 ∗∗,
SbB∗∗
ADOS-Play 0.24 0.004 1.20 + 0.540PbB + 4.23Sb9 + 0.0017Glut PbB∗
ADOS-SBRI 0.21 0.02 4.64–0.897HgB − 2.63CdB − 0.26AlB + 0.050Pb9 + 0.730Hg9
∗∗∗P<. 001, ∗∗P<. 01, ∗P<. 05
(each of which was taken form a sample of size 40 or more)
would come from a distribution with mean 0 and standard
deviation equal to 0.02. Under those conditions, the P-value
for a mean correlation coeﬃc i e n to f0 . 1 4i sl e s st h a t1 0
−10,s o
again it is extremely likely that there is a high overall positive
correlation between the severity measures as a group and the
biological measures taken as a group.
Since multiple correlations were obtained, it was decided
to conduct regression analyses, which are discussed in the
next section. Basically, a regression analysis allows for the
simultaneous consideration of multiple factors, such as how
well certain combinations of diﬀerent toxic metal excretions
can predict values of a speciﬁc autism severity measure.
3.3. Regression Analyses of Initial Severity of Autism. Table 5
shows the results of stepwise linear regression analyses for
the various autism severity scales as a function of urinary
excretion of toxic metals (at baseline and after the 9th dose
of DMSA) and initial glutathione. All of the analyses found
that the variations in the severity of autism could be partially
explained by the urinary excretion of toxic metals and initial
glutathione, with adjusted R2 values ranging from 0.22 to
0.45, and P-values all below .005. For the ADOS (which had
the highest adjusted R2), the most signiﬁcant variables were
mercury (Hg) and antimony (Sb) at baseline and mercury
and tungsten (W) at the 9th dose.
Since the ADOS score had the highest adjusted R2 values,
we also conducted a similar regression analysis on the
subscales—(a) language and communication; (b) reciprocal
social interaction; (c) play; (d) stereotyped behaviors and
restrictedinterests(SBRIs).ThoseresultsareshowinTable 6.
The variation in all four of the ADOS subscales could
also be partially explained by urinary excretion of toxic
metals and RBC glutathione (adjusted R2 of 0.21–0.41,
P<. 02 in all cases). The ADOS Sociability and the ADOS
Communication subscales had the highest adjusted R2 (0.41
and 0.37, resp.). For the ADOS Sociability subscale, the
most signiﬁcant variable was tungsten at the 9th dose,
followed by tungsten, aluminum, and thallium at baseline
and lead and thallium at the 9th dose. For the ADOS
Communicationsubscale,themostsigniﬁcantvariableswere
mercury (at baseline and 9th dose) and antimony (Sb) at
baseline.
Since the toxic metal excretions exhibit considerable cor-
relation amongst themselves [10], one should refrain from
reading too much into the relationships between speciﬁc
metals and severity of autism and instead should interpret
the results as indicating a general relationship between
autism severity and urinary excretion of toxic metals.
4. Discussion
The diﬀerent assessment tools were found to be highly
correlated, which generally supports the validity of each
of the assessment tools. The correlations were the highest
between the modiﬁed PDD-BI and the ATEC, suggesting
that those scales are very consistent. The ADOS had a lower
correlation with the other scales; this at least partly due to6 Journal of Toxicology
diﬀerent evaluator for the ADOS (assessed by a professional
certiﬁed in the ADOS) versus the ATEC, modiﬁed PDD-BI,
and SAS which were assessed by the same person (the parent
who was the primary care giver).
The various correlation analyses found that overall there
were multiple positive correlations between the severity of
autism and the urinary excretion of some toxic metals (both
before and after taking DMSA). Lead (after DMSA) and
antimony (at baseline) had the most consistent eﬀect, but
other metals were also important. The existence of multiple
positive correlations suggested that a regression analysis was
appropriate.
The regression analysis found that the body burden of
toxic metals (as assessed by urinary excretion before and
after DMSA) was signiﬁcantly related to the variations in
the severity of autism, for each of the four scales. The
metals of greatest inﬂuence were lead (Pb), antimony (Sb),
mercury(Hg),tin(Sn),andaluminum(Al).Diﬀerentmetals
are signiﬁcant for the diﬀerent scales, and this partial dis-
agreement is probably due to two factors. First, the severity
scales are not identical, having somewhat diﬀerent questions
and evaluating symptoms somewhat diﬀerently; as pointed
out in Table 3, the correlations between the scales are good
but not identical. Second, it should be noted that the high
correlation between urinary excretion of many of the metals
( s e eA d a m se ta l .[ 10]) makes it diﬃcult to separate the eﬀect
of one metal from another. This makes it improper to assign
too much meaning to speciﬁc regression variables and their
coeﬃcients. Thus, it is probably best to not overinterpret
the results in terms of a particular metal, but to instead
interpret them as evidence of the general role of toxic metals
inrelationtotheseverityofautism.Sinceoxidativestressand
thiol metabolic disturbances have both been described in the
autism population [12, 13], it is likely that these play a role in
both relative burden and susceptibility to heavy metals. And
since heavy metal exposure generates oxidative stress and
thiol depletion, the potential etiological role of metal cations
in generating autism symptoms should be further studied.
Similarly, prior depletion of thiols and increased oxidative
stress makes it more likely the individual will accumulate
metals.
It should also be noted that each severity scale assesses a
somewhat diﬀerent aspect of autism; for example, the ATEC
has a major section on physical health, which is not assessed
bytheotherscales.So,thatmayalsoexplainwhythediﬀerent
scales have somewhat diﬀerent relationships with diﬀerent
metals.
The ADOS had the highest adjusted R2 value, suggesting
thatitisaveryusefulscaleforassessingtheseverityofautism
and for inclusion in correlation and regression analyses with
biologicalfactors.Thismaybeduetothefactthat,ofthefour
tools we used, only the ADOS involves a trained professional
making a quantitative assessment of many children, whereas
the other tools are assessments by parents of only their child.
The strong correlation of the SAS with the other scales,
and the high adjusted R2 value (0.36), suggests that the
SAS is a useful tool for simple assessment of the severity of
autism.
We are aware of two other studies which found a
relationship between the severity of autism and a biomarker
related to heavy metal toxicity. One study by Geier et al.
[14] found that elevations in urinary porphyrins (associated
withmercuryorleadandmercurytoxicity)weresigniﬁcantly
associated with Childhood Autism Rating (CARS) scores.
A second paper to report a relationship of the severity
of autism with a biomarker was a study which found a
strong inverse relationship of the severity of autism with the
amount of mercury in the baby hair of the subjects [15].
However, a replication study [16] did not reproduce that
correlation with severity. So, while two studies [14, 15]d o
support a possible relationship of variations in the severity
of autism with body burden of toxic metals, as was found
in this paper, additional research is needed to conﬁrm this
ﬁnding.
This paper has focused on the possible relationship
between toxic metals and the severity of autism. It has not
included an examination of the source of those metals.
Mercury, lead, and other toxic metals come from many
sources. There has been particular interest in the possible
relationship of autism and thimerosal (a mercury-based
preservative once used in many childhood vaccines, but
removedfrommostvaccinesafter2003). However,thisstudy
wasnot designed to determine the sources of the toxic metals
found in children with autism.
4.1. Limitations of this Study. The original study was
designed primarily for evaluating the safety and eﬃcacy of
DMSA therapy. It was not primarily designed for investigat-
ing the relationship of the severity of autism to toxic metals,
but that was an interesting outcome, so we felt it worth while
to report it. Some limitations of the study design include the
following.
(1) The PDD-BI, SAS, and ADOS were assessed 2–
4 weeks after the ﬁrst round of DMSA, whereas
the ATEC was assessed before. However, the strong
correlation of the ATEC and PDD-BI suggests that
this was a minor issue, and that the initial round of
DMSA did not signiﬁcantly aﬀect the assessment.
(2) The ATEC involved the largest number of partic-
ipants (n = 63), whereas the other assessments
involved somewhat smaller numbers (n = 49).
5. Conclusions
Overall, the correlation analysis found multiple signiﬁcant
correlations of severity of autism and the urinary excretion
of toxic metals, such that a higher body burden of toxic
metals was associated with more severe autistic symptoms.
The results of the regression analyses (P<. 005 in all cases)
indicate that variations in the severity of autism may be
partially explained in terms of toxic metal body burden.
However, the ﬁnding of a relationship does not establish
causality.Journal of Toxicology 7
Acknowledgments
First and foremost, the authors thank the many autism
families and their friends who volunteered as participants
in this research study. They thank the Wallace Foundation
and the Autism Research Institute for ﬁnancial support of
this study. They thank Nellie Foster of SCNM for help with
blood draws. They thank Women’s International Pharmacy
for assistance with compounding the DMSA individually for
each child. They thank Spectrum Chemicals for providing
the DMSA. They thank Doctor’s Data and Immunosciences
for providing testing at reduced cost. They thank the Autism
Society of America—Greater Phoenix Chapter and the
ArizonaDivisionofDevelopmentalDisabilities fortheirhelp
with advertising the study.
References
[1] S. Bernard, A. Enayati, L. Redwood, H. Roger, and T. Bin-
stock, “Autism: a novel form of mercury poisoning,” Medical
Hypotheses, vol. 56, no. 4, pp. 462–471, 2001.
[2] G. C. Windham, L. Zhang, R. Gunier, L. A. Croen, and
J. K. Grether, “Autism spectrum disorders in relation to
distribution of hazardous air pollutants in the San Francisco
Bay area,” Environmental Health Perspectives, vol. 114, no. 9,
pp. 1438–1444, 2006.
[3] M. C. DeSoto and R. T. Hitlan, “Blood levels of mercury are
related to diagnosis of autism: a reanalysis of an important
data set,” Journal of Child Neurology, vol. 22, no. 11, pp. 1308–
1311, 2007.
[ 4 ] J .B .A d a m s ,J .R o m d a l v i k ,V .M .S .R a m a n u j a m ,a n d
M. S. Legator, “Mercury, lead, and zinc in baby teeth of
children with autism versus controls,” Journal of Toxicology
and Environmental Health Part A, vol. 70, no. 12, pp. 1046–
1051, 2007.
[5] J. Bradstreet, D. A. Geier, J. J. Kartzinel, J. B. Adams, and
M. R. Geier, “A case-control study of mercury burden in
childrenwithautisticspectrumdisorders,”JournalofAmerican
Physicians and Surgeons, vol. 8, no. 3, pp. 76–79, 2003.
[6] C. Lord, M. Rutter, S. Goode, et al., “Autism diagnostic obser-
vationschedule:astandardizedobservationofcommunicative
and social behavior,” Journal of Autism and Developmental
Disorders, vol. 19, no. 2, pp. 185–212, 1989.
[ 7 ]I .L .C o h e n ,S .S c h m i d t - L a c k n e r ,R .R o m a n c z y k ,a n dV .
Sudhalter, “The PDD behavior inventory: a rating scale for
assessing response to intervention in children with pervasive
developmental disorder,” Journal of Autism and Developmental
Disorders, vol. 33, no. 1, pp. 31–45, 2003.
[8] B. Rimland and S. Edelson, Autism Treatment Evaluation
Checklist: Statistical Analyses, Autism Research Institute, San
Diego, Calif, USA, 2000.
[9] R. K. Zalups, “Inﬂuence of 2,3-dimercaptopropane-1-
sulfonate (DMPS) and meso-2,3- dimercaptosuccinic acid
(DMSA) on the renal disposition of mercury in normal
and uninephrectomized rats exposed to inorganic mercury,”
Journal of Pharmacology and Experimental Therapeutics, vol.
267, no. 2, pp. 791–800, 1993.
[10] J.B.Adams,M.Baral,E.Geis,etal.,“Safetyandeﬃcacyoforal
DMSA therapy for children with autism spectrum disorders:
part A—medical results,” in submission.
[11] J.B.Adams,M.Baral,E.Geis,etal.,“Safetyandeﬃcacyoforal
DMSA therapy for children with autism spectrum disorders:
part B—behavior results,” in submission.
[12] S. J. James, P. Cutler, S. Melnyk, et al., “Metabolic biomark-
ers of increased oxidative stress and impaired methylation
capacity in children with autism,” American Journal of Clinical
Nutrition, vol. 80, no. 6, pp. 1611–1617, 2004.
[13] S. J. James, S. Melnyk, S. Jernigan, et al., “Metabolic endophe-
notype and related genotypes are associated with oxidative
stress in children with autism,” American Journal of Medical
Genetics Part B, vol. 141, no. 8, pp. 947–956, 2006.
[14] D. A. Geier, J. K. Kern, C. R. Garver, et al., “Biomarkers of
environmentaltoxicityandsusceptibilityinautism,”Journalof
the Neurological Sciences, vol. 280, no. 1-2, pp. 101–108, 2009.
[15] A. S. Holmes, M. F. Blaxill, and B. E. Haley, “Reduced
levels of mercury in ﬁrst baby haircuts of autistic children,”
International Journal of Toxicology, vol. 22, no. 4, pp. 277–285,
2003.
[16] J. B. Adams, J. Romdalvik, K. E. Levine, and L.-W. Hu,
“Mercury in ﬁrst-cut baby hair of children with autism versus
typically-developing children,” Toxicological and Environmen-
tal Chemistry, vol. 90, no. 4, pp. 739–753, 2008.